AMYPAD Prognostic and Natural History Study (PNHS)

  • Research type

    Research Study

  • Full title

    AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study in individuals without dementia to evaluate the additional value of quantitative amyloid imaging in determining Alzheimer’s Disease (AD) dementia risk.

  • IRAS ID

    230209

  • Contact name

    Laura Doull

  • Contact email

    lauradoull1@gmail.com

  • Sponsor organisation

    Stichting VUmc

  • Eudract number

    2018-002277-22

  • Clinicaltrials.gov Identifier

    EudraCT number, 2018-002277-22

  • Duration of Study in the UK

    2 years, 10 months, 1 days

  • Research summary

    Alzheimer's Disease (AD) is the most common cause of dementia worldwide, affecting 1 in 10 people aged 65 years or older. Certain brain changes have been associated with AD; however, the brain changes as we age, even in people who never develop dementia. The build-up of a protein called β-amyloid in the brain is believed to be one of the earliest detectable brain changes associated with AD development. Positron Emission Tomography (PET) is a type of scan which makes images of the brain. In this study, we'll use β-amyloid PET imaging to better understand the changes in the brain that are related to the development of AD dementia and identify people who are at increased risk of such a progression.

    This study is a study linked to the European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS), and will take place in up to 20 research centres in France, the Netherlands, Spain, Sweden, Switzerland, Germany, Denmark, Norway, Finland, Italy, Ireland, Belgium and the UK. We’re doing this study in up to 2000 participants, without dementia, from among the EPAD LCS participants. Participants will continue to have the procedures required for EPAD LCS and will have up to 2 amyloid PET scans as part of AMYPAD PNHS.
    Participants will take up to 25 months to finish the study. They'll all have 1 screening visit and 1 study visit involving an amyloid PET scan. Half of the participants will then be invited back for a second study visit to have a second PET scan between 12-24 months after their first PET scan (Study Visit 1). For each PET scan, participants will receive a dose of radioactive tracer.

  • REC name

    Scotland A: Adults with Incapacity only

  • REC reference

    18/SS/0142

  • Date of REC Opinion

    19 Dec 2018

  • REC opinion

    Favourable Opinion